Author:
Kim Sukyung,Kang Bae-Gon,Sa Soonok,Park Se Young,Ryu Kyungheon,Lee Jinyoung,Park Boram,Kwon Mijeong,Kim Yeonghee,Kim Jiwon,Shin Sanghee,Jang Sehun,Kim Byung Eui,Bae Jaewoong,Ahn Kangmo,Liu Kwang-Hyeon,Kim Jihyun
Abstract
IntroductionThe effects of fructo-oligosaccharides (FOS) on atopic dermatitis (AD) have not been determined.MethodsIn a randomized, double-blind, placebo-controlled trial, children with AD aged 24 months to 17 years received either advanced FOS containing 4.25 g of 1-kestose or a placebo (maltose) for 12 weeks.ResultsThe SCORAD and itching scores were reduced in patients treated with both FOS (all p < 0.01) and maltose (p < 0.05 and p < 0.01). Sleep disturbance was improved only in the FOS group (p < 0.01). The FOS group revealed a decreased proportion of linoleic acid (18:2) esterified omega-hydroxy-ceramides (EOS-CERs) with amide-linked shorter chain fatty acids (C28 and C30, all p < 0.05), along with an increased proportion of EOS-CERs with longer chain fatty acids (C32, p < 0.01).DiscussionFOS may be beneficial in alleviating itching and sleep disturbance, as well as improving skin barrier function in children with AD.